CSF2 and metastatic melanoma: A pilot study demonstrated that the sequential therapeutic strategy combining cryoablation followed by intralesional administration of granulocyte-macrophage colony-stimulating factor (GM-CSF) at a standardized dose of 500 mcg exhibited well tolerability and efficacy in patients with unresectable metastatic melanoma (46).